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Abstract:
Central injections of Pituitary adenylate cyclase-activating polypeptide
(PACAP) into the ventromedial nuclei (VMN) of the hypothalamus produce
hypophagia that is dependent upon the PAC1 receptor, however, the signaling
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downstream of this receptor in the VMN is unknown. Though PACAP signaling
has many targets, this neuropeptide has been shown to influence glutamate
signaling in several brain regions through mechanisms involving NMDA
receptor potentiation via activation of the Src family of protein tyrosine
kinases. With this in mind, we examined the Src-NMDA receptor signaling
pathway as a target for PACAP signaling in the VMN that may mediate its
effects on feeding behavior. Under nocturnal feeding conditions, NMDA
receptor antagonism prior to PACAP administration into the VMN attenuated
PACAP-mediated decreases in feeding suggesting glutamatergic signaling via
NMDA receptors is necessary for PACAP-induced hypophagia. Furthermore,
PACAP administration into the VMN resulted in increased tyrosine
phosphorylation of the GluN2B subunit of the NMDA receptor, and inhibition of
Src kinase activity also blocked the effects of PACAP administration into the
VMN on feeding behavior. These results indicate that PACAP
neurotransmission in the VMN likely augments glutamate signaling by
potentiating NMDA receptors activity through tyrosine phosphorylation events
mediated by the Src kinase family, and modulation of NMDA receptor activity
by PACAP in the hypothalamus may be a primary mechanism for its regulation
of food intake.
Keywords: feeding, VMN, glutamate, Src kinase, PACAP.

Introduction
Hypothalamic glutamate neurotransmission is crucial to energy
balance [1-6], in part, through the regulation of feeding behavior [79]. This is in contrast to classical views of hypothalamic signaling that
have focused on the importance of neuropeptides for homeostatic
regulation. However, recent investigations into mechanisms of
neuropeptide function have indicated that modulation of the fastacting amino acid neurotransmitters, glutamate and GABA, may be a
primary role for neuropeptide signaling [10]. For example, the
neuropeptides orexin and neuropeptide Y (NPY) both potently increase
feeding behavior through glutamate receptor-dependent signaling
pathways in the lateral hypothalamus [11, 12] and that orexin causes
enhancement of presynaptic glutamate release and postsynaptic NMDA
receptor activity in the ventral tegmental area [13].
The hypothalamic ventromedial nuclei (VMN) are critical
regulators of body weight and possess both high levels of glutamate
and all glutamate receptor subtypes [4, 14-16]. Stimulation of these
nuclei produces reductions in food intake and increased metabolic rate
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[8, 17-20]. Likewise, microinjection of the pleiotropic neuropeptide
pituitary adenylate cyclase-activating polypeptide (PACAP) into the
VMN inhibits feeding behavior through activation of PAC1 receptors
even after food deprivation [21, 22], however, the VMN neuronal
signaling downstream of PAC1R leading to decreased food intake is
currently unknown. However, previous demonstration of synergy
between PACAP and glutamate [23-25] in other brain regions suggests
that PACAP-PAC1R signaling in the VMN may lead to augmented
glutamate neurotransmission.
Co-localization of PACAP and glutamate immunoreactivity in
retinal ganglion cells, as well as in nerve terminals located in the
suprachiasmatic nuclei (SCN) support a mechanism of co-release at
synapses of the retinohypothalamic tract [23, 26, 27]. Functionally,
PACAP application to SCN slices produces dose-dependent phase shifts
in circadian rhythms through modulation of NMDA receptor activity
[24]. In another brain region, PACAP enhances NMDA receptor activity
in the hippocampus, reportedly by two separate mechanisms involving
Src tyrosine kinase signaling. The first of which involves cAMP/PKAdependent activation of Fyn, a member of the Src tyrosine kinase
family, leading to phosphorylation of multiple tyrosine residues on the
GluN2B subunit of the NMDA receptor [28], while the second was
shown to occur via PAC1R activation of a phospholipase C pathway
leading to Src tyrosine kinase activation and augmented hippocampal
NMDA receptor function [25]. Both PACAP-mediated signaling
pathways reported in the hippocampus suggest that modulation of
NMDA receptors can occur through Src family kinase activity, which
has been implicated in the regulation of feeding behavior by lateral
hypothalamic neurons [29].
In order to determine whether modulation of glutamatergic
NMDA receptor signaling underlies the regulation of feeding behavior
by PACAP in the hypothalamus we measured nocturnal food intake
following pharmacological inhibition of NMDA receptor function within
the VMN prior to PACAP injection. Moreover, we analyzed tyrosine
phosphorylation of NMDA receptors following PACAP administration
and examined whether activity of Src family kinases is important for
PACAP-mediated alterations of feeding behavior in the VMN. Our
results suggest that NMDA receptor activity is necessary for PACAP-
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induced hypophagia in the VMN, and PACAP may act through
stimulation of Src kinases to augment NMDA receptors function.

Methods
Animals
Male Sprague-Dawley rats (Harlan; Madison, WI) weighing 225250 g were individually housed in a climate controlled room with a 12
hr light/dark cycle. Animals had free access to Harlan standard diet
(8604 formulation) and water. Food consumption was measured with a
BioDAQ Food Intake Monitor (Research Diets; New Brunswick, NJ) or
calculated by pre-weighing food in each bin and subtracting the weight
of non-ingested and spilled food at the end of each measurement
period. All procedures using animals were approved by the Marquette
University Institutional Animal Care and Use Committee.

Surgery
Animals were anesthetized with a ketamine/xylazine/acepromazine
(77:1.5:1.5 mg/ml/kg; ip) cocktail and placed in a stereotaxic
apparatus. Bilateral guide cannulae (26 gauge; Plastics One; Roanoke
VA) were placed 3 mm dorsal to the target site in all animals, and
secured to the surface of the skull with an acrylic resin. The
stereotaxic coordinates for the VMN were anterior/posterior, -2.5 mm
from bregma; medial/lateral, 0.6 mm from midline; dorsal/ventral, 6.2 mm from surface of the skull based on The Rat Brain in Stereotaxic
Coordinates, 6th Edition [30]. Injectors extended 3 mm past the
ventral tip of the cannulae reaching a VMN injection site of -9.2 mm
ventral from the surface of the skull. The upper incisor bar was
positioned -3.3 mm below horizontal zero. A bilateral dummy stylet
placed in the guide cannulae was used to maintain patency. All
animals were given at least five days to recover after cannula
installation before receiving drug or vehicle injections, during which
time the animals were handled and dummy stylets were removed and
replaced daily in order to acclimate the animals to the physical
handling necessary during experiments. Correct cannulae placements
were confirmed at the conclusion of each experiment by microscopic
examination of Nissl stained sections and only those with correct
placement were included in the studies.
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Feeding Behavior Experiments
Animals were weighed daily and acclimated to the BioDAQ Food
Intake Monitor for at least 7 days before the onset of the experiment.
In all experiments, approximately 1 hour prior to lights off rats
received bilateral microinjections of vehicle, D-(-)-2-amino-5phosphonopentanoic acid (AP5; 10 pmol - 1 nmol in saline/0.25
µl/side; Tocris Bioscience), or 1-(1,1-Dimethylethyl)-1-(4methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1; Src kinase
inhibitor; 1 - 100 pmol in 10 % DMSO/0.25 µl/side; 1 nmol in 25%
DMSO/0.25 µl/side; Tocris Bioscience) over approximately two minutes
in awake animals while gently restrained. When necessary, DMSO was
used as a vehicle for water insoluble substances such as PP1, as it has
been previously verified to be suitable for such feeding experiments,
causing no significant alterations in food intake when administered
alone, even with solutions at concentrations as high as 75% [29, 31].
Upon completion of antagonist/inhibitor injections an additional minute
elapsed before removing injectors to minimize backflow of injected
material. Five minutes later (15 minutes for PP1 studies) rats received
a second bilateral injection of either saline or PACAP (50 pmol/0.25
µl/side; PACAP38; California Peptide Research; Napa, CA) and upon
completion animals were returned to their home cage for subsequent
feeding measurements. The optimal injection volume of 0.25 µl to
contain microinjections within VMN was determined previously [21].
Feeding measurements were collected for the next 24 hours, with the
greatest emphasis placed on the first 3-5 hours after microinjections
were delivered.

Western blot analysis of GluN2B tyrosine
phosphorylation
Thirty minutes following saline or PACAP (50 pmol/0.25 µl/side)
injections into the VMN, bilateral dissections of the ventromedial
hypothalamus (VMH; including the VMN and surrounding areas) were
collected. VMH tissue was homogenized by hand (10 strokes) in icecold homogenization buffer (320 mM sucrose, 10 mM Tris-HCl, pH 7.4,
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10mM EDTA, 10mM EGTA) containing Halt protease and phosphatase
inhibitor cocktail (Pierce; Rockfork, IL), followed by 3-4 seconds of
sonication. Homogenates were centrifuged at 1000 X g for 2 minutes
at 4° C to remove nuclei and large debris. The resulting supernatant
was further centrifuged at 10,000 X g for 30 minutes at 4° C to obtain
a crude membranal pellet that was resuspended in solubilization buffer
(1% Triton x-100, 150 mM NaCl, 10nM Tris-HCl pH 7.4, 1 mM EDTA, 1
mM EGT, protease & phosphatase inhibitor cocktail). Protein
quantification of samples was determined using a bicinchoninic (BCA)
assay (Pierce). Membrane protein (20 µg) was run on an 8% gel by
SDS-PAGE and transferred to a polyvinylidine fluoride (PVDF)
membrane. Membranes were blocked with 5% bovine serum albumin
(BSA) in tris-buffered saline containing 0.1 % Tween-20 (TBS-T). Blots
were then probed with rabbit anti-pY1336 GluN2B antibody (Rockland
Immunochemicals; Gilbertsville, PA) overnight at 4° C, followed by
washes with TBS-T and incubation with an HRP-conjugated mouse
anti-rabbit secondary antibody (Jackson Immunoresearch; West
Grove, PA) at room temperature for 2 hours. Band intensities for
pY1336 were developed using SuperSignal West Femto
chemiluminescent substrate (Pierce) and visualized using the Kodak
Image Station 4000MM. After visualization of pY1336 signal, blots
were stripped and reprobed in an identical fashion for total GluN2B
expression using mouse anti-GluN2B (Rockland Immunochemicals)
and HRP-conjugated goat anti-mouse (Jackson Immunoresearch)
antibodies. Band densities were measured using Kodak Molecular
Imaging Software v4.0.

Statistics
Data are presented as means ± standard errors of the mean,
and were analyzed statistically by analysis of variance (with repeated
measures when appropriate). Fischer LSD analysis was used for all
post-hoc group comparisons. Statistical analyses were performed
using Sigma Plot 11 software (Systat Software Inc.; San Jose, CA). P
< 0.05 were considered statistically significant.

Results
Our previous efforts to characterize the effects of PACAP
signaling in the hypothalamus have demonstrated a PAC1R-dependent
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decrease in food intake following site-specific injections into the VMN
[21, 22]. Considering previous associations between PACAP and NMDA
receptor signaling [24, 25, 28, 32], as well as the potential of NMDA
receptor activity to regulate feeding behavior [11, 12, 29, 33], we
proceeded to test whether glutamate signaling via the NMDA receptor
was necessary for PACAP-mediated reductions in food intake. Initially,
the NMDA receptor antagonist AP5 was administered bilaterally into
the VMN at multiple doses ranging from 10 pmol to 1 nmol to
investigate its contribution to normal nocturnal feeding behavior.
Surprisingly, none of the three doses tested significantly altered
feeding behavior (Fig. 7.4A). To determine whether NMDA receptor
function is necessary for PACAP-mediated decreased food intake,
animals received AP5 (10 pmol/side) injections into the VMN prior to
PACAP (50 pmol/side). Although AP5 treatment alone again had no
effect on feeding, it did successfully block the effects of PACAP
injections into the VMN on food intake (Fig. 7.4B; P < 0.05).
With the evidence that NMDA receptor function appears to be
necessary for decreased food intake induced by PACAP, we examined
whether similar mechanisms of NMDA receptor potentiation by PACAP
existed within the hypothalamus as has been reported in the
hippocampus [25, 28]. PACAP treatment of hippocampal slices was
found to produce increased phosphorylation of tyrosines 1252, 1336,
and 1472 specifically on the GluN2B subunit of NMDA receptors [28],
therefore to test for tyrosine phosphorylation under our conditions we
performed microinjections of saline or PACAP in a similar manner prior
to feeding experiments but collected VMH tissue 30 minutes postinjection for GluN2B tyrosine phosphorylation analysis. In western
blotting experiments we examined phosphorylation levels of tyrosine
1336 (pY1336) on the GluN2B subunit of the NMDA receptor and
normalized band intensities to total GluN2B expression. Indeed, semiquantitative analysis demonstrated that VMN PACAP treatment
increased pY1336 expression by approximately 25% (Fig. 7.5A & B; P
< 0.05).
Tyrosine phosphorylation of the NMDA receptor mediated by
PACAP signaling has been associated with increased Src family kinase
activity [25, 28], which has also been implicated in the regulation of
feeding behavior by the lateral hypothalamus [29]. Supported by the
studies conducted in the hippocampus [28] as well as the data
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presented here, the phosphorylation appears to be specific to the
GluN2B subunit of the NMDA receptor. Taken together it is probable
that PACAP-PAC1R signaling results in tyrosine phosphorylation of the
GluN2B subunit of the NMDA receptor in the VMN through activation of
an Src kinase. To confirm this possibility the Src kinase inhibitor PP1
(1 - 1000 pmol/0.25 µl/side) was injected into the VMN followed by
measurements of food intake. No concentration of PP1 used in these
studies significantly altered food intake when injected into the VMN
alone (Fig. 7.6A). However, pretreatment with PP1 (10 pmol/side) in
the VMN prior to PACAP injections did significantly attenuate the
hypophagic effects of PACAP (Fig. 7.6B; P < 0.05).

Discussion
By inhibiting NMDA receptor signaling we were able to examine
the contribution of its activity to PACAP-mediated decreases in food
intake in the VMN. Pretreatment with the NMDA receptor antagonist
AP5 successfully attenuated the hypophagic response to PACAP
administration into the VMN. These data build upon previous findings
indicating that PACAP-PAC1R signaling may potentiate postsynaptic
NMDA receptor activity (Figure 4) [24, 25, 32], perhaps through
phosphorylation of the GluN2B subunit [28]. Upon examination of
GluN2B phosphorylation following PACAP injections into the VMN in
vivo, we detected an increase in phosphorylation at tyrosine 1336, a
previously identified site of PACAP-induced tyrosine phosphorylation on
the GluN2B subunit of the NMDA receptor [28]. Not only has the Src
family of non-receptor tyrosine kinases been previously described to
facilitate NMDA receptor phosphorylation mediated by PACAP [25, 28],
but hypothalamic Src activity has been demonstrated to play a role in
the regulation of feeding behavior [29]. These findings led us to test
whether Src was a downstream mediator of PACAP-induced
hypophagia in the VMN. Inhibition of Src family tyrosine kinases with
PP1 effectively blocked the effects of intra-VMN PACAP on feeding
behavior, thus supporting a mechanism for PACAP-mediated
potentiation of NMDA receptors via an Src-dependent pathway.
Similar to our current data combining NMDA receptor
antagonists with PACAP injections into the VMN, inhibition of NMDA
receptors also blocks hyperphagia induced by orexin and neuropeptide
Y in the lateral hypothalamus as well as refeeding following a fast [11,
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12]. In contrast, AMPA/kainate and NMDA glutamate receptor agonists
produce robust feeding in sated rats when administered into the lateral
hypothalamus [7, 33, 34]. Although treatment with AP5 in the VMN did
not produce increased feeding behavior as one might expect, AP5 was
administered at a time when feeding behavior was naturally at its
peak, possibly reducing our ability to detect AP5-induced alterations in
feeding behavior. However, our current findings indicate that VMN
PACAP injections produce NMDAR-dependent hypophagia and GluN2B
tyrosine phosphorylation, and that NMDA receptors in the VMN
significantly regulate feeding behavior. In the lateral hypothalamus,
antagonism of GluN2B containing NMDA receptors with ifenprodil
attenuates the feeding response to both fasting and microinjection of
NMDA into the lateral hypothalamus, although ifenprodil
concentrations used in these studies may have also antagonized
GluN2A containing NMDA receptors [36]. The phosphorylation state of
the GluN2B subunit may be critical for augmenting NMDA receptor
activity induced by PACAP signaling, and appears to be regulated by
the Src family of tyrosine kinases [25, 28], a family of kinases that is
critical to the function and signaling of NMDA receptors also reported
to reduce GluN3A trafficking to the synaptic membrane [37-39].
Importantly, inhibition of Src family tyrosine kinases by PP1 has
previously been reported to block NMDAR-dependent feeding behavior
in the lateral hypothalamus [29], similar to our data regarding PACAP
signaling in the VMN.
Although our investigations of PACAP-mediated feeding behavior
in the VMN cannot directly demonstrate potentiation of postsynaptic
NMDA receptors by PACAP signaling, extensive biochemical and
electrophysiological analysis of glutamate signaling in the hippocampus
has demonstrated this modulatory pathway. PACAP application yields
enhancement of field excitatory postsynaptic potentials, brain derived
neurotrophic factor mRNA expression, and tyrosine phosphorylation of
the GluN2B subunit of the NMDA receptor by Fyn tyrosine kinase,
which is a member of the Src family of tyrosine kinases [28]. Further
coupling PACAP to glutamate signaling, PACAP augments NMDA
currents following Schaffer collateral stimulation through a PAC1Rdependent pathway that activates Src tyrosine kinase [25]. While two
different mechanisms of NMDA receptor potentiation by PACAP have
been identified, both occur as a result of tyrosine phosphorylation of
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NMDA receptors by a member of the Src family of tyrosine kinases
(Fyn and Src).
PACAP signaling may also modulate other aspects of glutamate
signaling including the AMPA receptor, as PAC1R-dependent
potentiation of AMPA receptors at low PACAP concentrations and
VPAC2R-mediated depression of AMPA receptors at high
concentrations of PACAP have been reported in the hippocampus [40].
Furthermore, excitatory transmission from the basolateral amygdala to
the central amygdala is augmented through PACAP-VPAC1R increases
in AMPA receptor activity [41]. However, without further behavioral
pharmacology examining glutamate receptor-mediated properties of
PACAP-induced hypophagia in combination with the appropriate
electrophysiology, the role of other modes of glutamatergic
neurotransmission cannot be ascertained at this time. Nevertheless,
our experiments using AP5 and PP1 attenuated the effects of PACAP on
feeding suggesting a similar mechanism of NMDA receptor modulation
by PACAP likely exists in the hypothalamus as it does in the
hippocampus.
Glutamate is also substantially regulated by astrocytes, which
are major targets of PACAP signaling [42-44], yielding another
potentially important mechanism for glutamate modulation by PACAP.
Astrocytes impact glutamate neurotransmission most notably through
removal of synaptic glutamate by sodium-dependent excitatory amino
acid transporters (EAATs) [45-47] and glutamate release from
astrocytes themselves [48-52]. Given that a single astrocyte can
interact with numerous synapses [53, 54], their influence over
glutamate signaling and overall network activity is immense. PACAP is
already known to increase expression of both GLAST and GLT-1
(EAAT1 and EAAT2 respectively) in primary cortical astrocyte cultures
[55], therefore, investigation into how astrocytic glutamate regulation
is further influenced by PACAP may reveal new insights into signaling
mechanisms that are important to glutamate homeostasis and may
influence behavior. Despite the extensive study of how astrocytic
control of glutamate affects hypothalamic function [6, 56-58] and
knowledge that PACAP potently regulates feeding behavior [22, 5961], whether or not modulation of astrocytic glutamate signaling by
PACAP influences food intake has yet to be investigated.
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The studies described here further our understanding of PACAP
signaling in the hypothalamus with regard to feeding behavior.
Previous reports have suggested that PACAP augments NMDA receptor
activity [24, 25, 28, 32]. In the current study, inhibition of NMDA
receptor signaling is sufficient to mitigate the hypophagic response to
PACAP administration in the VMN suggesting a similar relationship
exists between PACAP and NMDA receptor signaling in the
hypothalamus. Furthermore, this NMDA receptor modulation by PACAP
appears to be mediated through Src family kinase signaling, which is
critical to both NMDA receptor function as well as the regulation of
feeding behavior [29, 38, 39]. Given the identified pleiotropic actions
of PACAP, further investigation is warranted to address other
mechanisms of glutamate modulation by this neuropeptide and how
such mechanisms are involved in the regulation of feeding behavior.
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Figure Legends
Figure 1. NMDA receptor antagonism attenuates the hypophagic
effects of PACAP administration into the VMN. (A) Feeding responses
to a dose-response of bilateral AP5 microinjections into the VMN. (B)
Bilateral injection of 10 pmol AP5 into the VMN blocks the inhibitory
effect of PACAP on feeding behavior. Data are expressed as mean 
SEM. * = P < 0.05 compared to control group.
Figure 2. PACAP administration into the VMN results in increased
tyrosine phosphorylation of the GluN2B subunit of the NMDA receptor.
(A) Representative VMH protein samples from saline or PACAP (50
pmol/side) microinjections into the VMN probed for phosphorylation of
tyrosine 1336 of the GluN2b subunit (pY1336) and total GluN2B
protein expression. (B) Semi-quantitative analysis of band densities for
pY1336 normalized to total GluN2b expression expressed as a percent
of saline treatment. Data are expressed as mean  SEM. * = P < 0.05
Figure 3. Inhibition of Src kinase activity with PP1 attenuates PACAPinduced decreases in food intake in the VMN. (A) Feeding response to
PP1 injections into the VMN. (B) Pretreatment of the VMN with PP1
prior to PACAP injections prevents PACAP-mediated hypophagia. Data
are expressed as mean  SEM. * = P < 0.05 compared to control
group.
Figure 4. Modulation of NMDA receptor signaling by PACAP. (A)
Conventional glutamatergic synapse showing no modulation of
glutamate neurotransmission leading to lesser excitatory postsynaptic
potential (EPSP). (B) Proposed potentiation of EPSP following
modulation of glutamate receptors by PACAP released from glutamate
and PACAP co-expressing neurons or PACAPergic neurons.
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